Rebirth of the God-level Xueba

"How do you want to bet?" Raymond almost lay on the table.

"First is the first clinical phase. If you can guarantee the time and resources, I promise that there must be active substances that pass the first clinical phase, otherwise, I don't want a penny." Yang Rui said the whole table was dumbfounded.

Raymond subconsciously picked up a piece of his belly, chewing on it, and said: "A milestone payment method? Yes, but no penny? No payment?"

The milestone payment method can be said to be a kind of payment according to the progress, but it is different from the ordinary phased payment. The milestone established in advance is not necessarily related to the overall progress or the overall progress.

This method also often appears in international projects, such as building a railway, if it is paid in stages, such as completing one-fifth of the length, although the corresponding payment will be obtained, the engineering party still bears the complete project. Otherwise, you will inevitably suffer compensation and the money you received before will also be thrown away. However, if it is a milestone payment, the engineering side has not completed the responsibilities of the whole project, and those who do not want to do it or can't finish it, just turn around and leave.

Pharmaceutical companies generally make milestone payments, because no one can guarantee that a drug will be on the market, let alone the sales after it is on the market.

Yang Rui was extremely confident, and said: "It's up to you to decide, I can give up the payment, but if the active substance passes in the first phase of the clinical trial, I will ask for 20 million US dollars."

"Hey, brother, slow down." The Italian shouted as if he was suddenly hit by F1, "200,000 dollars to buy the first phase of the clinical trial? It's a bit expensive."

"There was no payment of 20,000 US dollars. Of course, the payment of 120,000 US dollars and the clinical milestone of 60 million US dollars, I have no problem." Yang Rui shrugged.

The Italian calculated that the milestone of 20 million dollars for a payment seemed to be a good deal, so he spread his hands and spoke in Italian.

Arnold slowed down at this time and said: "The payment of 120,000 US dollars is a little more. The payment of 100 million US dollars, the milestone of 50,000 US dollars, is willing to accept."

Although it was a bargain, it was also Arnold's gesture of good.

After all, someone counter-offering means establishing a bottom line. Although this bottom line is indeed very low.

However, it is also because Yang Rui's price is low enough that Arnold will bargain and show good.

In the process of new drug prescribing, pre-clinical research accounts for about 10% to 15% of the entire prescribing cost, usually 13%.

In the 1980s, the cost of prescribing a new drug was more than US$100 million, and the cost of prescribing a pure new drug was usually over US$200 million, with a few of them reaching US$500 million. Calculated based on this cost, the work currently completed by Huarui Lab should be valued at US$260,000.

However, this is the price of ordinary drugs. As a rare drug, desferiprone has a relatively weak profit prospect. Therefore, Yang Rui offered a lower price, which was alluring.

Seeing that everyone had no other opinions, Yang Rui nodded and said: "That's it, a no-payment gambling agreement with active substances is passed, no matter how many kinds, the milestone is 20 million US dollars."

"Category B includes a payment gambling agreement, pay 100 million US dollars, regardless of whether the active substance is passed, you will have to pay 100 million US dollars, but if two active substances pass, the milestone is 50 million US dollars. Three active substances pass, the milestone 100 million U.S. dollars, and so on. If all seven active substances pass the first clinical phase, an increase of 300 million U.S. dollars will be required."

"No!"

"This is too high!" Everyone at the table objected.

The Japanese even stood up and said: "According to this calculation, Class B may have to pay a milestone of 400,000 US dollars."

"Seven active substances passed in the first phase of the clinical trial, and they paid 400,000 US dollars. Not too much, isn't it?" Yang Rui said indifferently.

"Too much, too much." The Japanese shook his head, and said: "And there are too many seven active substances."

"No one thinks that there are too many active substances. Besides, this is only the first phase of the clinical trial. It's not a big deal with more bargaining chips and a little more money. Right." Yang Rui chuckled lightly.

"No, we can't afford the cost of such a rapid growth." The Japanese shook his head vigorously.

The Norwegians and Germans also raised objections, demanding a reduction in the amount of milestones.

Although the probability of all seven active substances passing the first clinical phase is very low, the gambling itself is just a chance, and they certainly don't want to hang a sword on them.

In clinical trials, fraud is also very difficult and unnecessary.

First of all, relative to tens of millions of dollars, it is more important that all seven active substances pass the first phase of clinical trials. No company will save 50 million US dollars after one active substance has passed the clinical trial. Concealed.

Secondly, clinical trials are a very rigorous scientific research process. Although there is the possibility of cheating, if the agreement is signed properly, the whole process can be basically monitored. Moreover, many large companies subcontract clinical trials to professional third-party companies. This makes the cost of clinical trial fraud even higher.

Aoki Aoki from Fujisawa Pharmaceutical Industry Co., Ltd. considered for a long time, and said: "For every more active substance passed, we are willing to pay an additional $20 million milestone."

"All seven kinds of passes will give 120,000 more? Only 20 million more than type A? Impossible, the milestone of 30 million dollars will not work." With so many people present, only Yang Rui surely knew that the seven kinds must pass, so, After he answered very seriously, he said: "This is a gambling agreement. If you don’t like the gambling agreement, you can re-negotiate the overall price. Or you can choose a milestone and lock in the risk of the first phase of the clinical trial at US$20 million."

After a short pause, Yang Rui said again: "If you choose a milestone and pass it, in theory, you can directly resell the deferiprone to other companies. I think, 40 million or 50 million US dollars, someone will rush to ask for it. If it passes If there are a lot of active substances, it’s possible to double the price, right? This means that if you take 10 million US dollars, you can draw 20 million US dollars, or 40 million US dollars in prizes."

The cost of Phase 1 is the cheapest of Phase 4, because it only requires dozens of people to participate in the safety test, which can be done at about US$10,000.

Despite this, there are still very few drugs that can pass clinical phase I, and they are of great value.

Some companies are willing to buy such drugs in order to reduce the risk in the early stage.

Nafu Aoki stopped talking.

As Yang Rui said, although a type of milestone is expensive, Yang Rui received 20,000 yuan, which also means that the company that purchases deferiprone will earn at least 20,000 US dollars.

Instead, Yang Rui couldn't get the money. It was the time when the biggest loss occurred. The company that bought deferiprone would bear a risk of US$10 million for this.

The gambling agreement can reduce costs the most, and they can eventually sell the risk of gambling to other financial companies or insurance institutions. Therefore, as long as the price of gambling is not too high, large pharmaceutical companies always have room for profit.

The overall purchase is different, and the risk is borne by the company itself. Unless the price is extremely cheap, it is not feasible at all.

"The increase in active substances can be divided into four or more, and four or less." The two Germans present were both younger, with a little English accent, and speaking slowly, and said: "I suggest. B milestones can also be used. There are two types, everyone is free to choose. Ba class according to Mr. Yang Rui said, for each more active substance passed, pay a certain amount of milestones to Huarui Laboratory, BB class, I want to bet on the passing of two active substances, Fewer than four."

The four active substances are more suitable for clinical trials, which can increase the pass rate of clinical trials without significantly increasing the cost of clinical trials.

Of course, the active material is always the best and the most, here is just a question of cost performance and probability.

Several people nodded in agreement.

Yang Rui concluded from Shanruliu: “Then there are two types, Ba, for each additional active substance, an increase of 50,000 US dollars, if all seven are passed, an additional US$30 million will be paid. For BB, there are two types of active substances that pass. , 40 million US dollars milestone, three active substances passed, 80 million US dollars milestone, four active substances passed, 120,000 US dollars milestone, five passes increased the milestone amount to 220,000, six passed 320,000, seven all passed, 42oo Ten thousand U.S. dollars."

The few people who heard the last number were secretly speechless, but no one objected. Seven active substances participate in the first phase of the clinical trial. It is better to pass four, but it is not surprising that there are two or three to pass. In this way, in the largest passing interval, if you bet on category B, two Pass will reduce the cost of 10 million US dollars, three passes will reduce the cost of 20 million US dollars, and the four can also save 30 million US dollars. Of course, five passes will increase spending by 20 million dollars, six through 70 million dollars, and seven through 120 million dollars. Although this is not a balanced stepped growth, milestones are inherently rewarding. If seven All the species passed, it can only show that the deferiprone made by Huarui Lab is very good, and it is worth more money.

More importantly, if the seven active substances are passed, it means that the company that pays the money will also make more money. The simplest resale is also necessary to make a profit of at least 40-50 million U.S. dollars.

"The specific amount is to be discussed, but we agree with this classification." Aoki Aoki from Fujisawa Pharmaceutical Co., Ltd. focused his head.

"If Huarui Laboratories cooperates with Zeleca, Zeleca will choose the Ba type agreement." Arnold couldn't wait to express his favor to Yang Rui.

It has to be said that the most sincere one is still Zeleca, and the Ba-type agreement currently seems to be the most favorable agreement for Yang Rui.

Raymond, who was also determined to win, sensed the crisis, took a deep look at Arnold, and turned his mind desperately.

Yang Rui only sighed inwardly.

Although Arnold tried his best to give good terms, in Yang Rui's view, the BB agreement is the most profitable agreement.

In the first phase of the clinical trial, there may be accidents that may cause one or two active substances to fail to pass, but the probability is really not high. After all, it is a safety experiment with only dozens of people participating. The compound is no problem or no problem. At most, it causes allergic reactions in some people. As long as it is not serious, it can still pass. There are basically no drugs that are completely free of allergic reactions.

Yang Rui really wants to bet against Zelican, and he is more willing to bet against BB agreements.

On the other hand, Arnold looked like a strong man who slaughtered his neck, Yang Rui couldn't laugh or cry.

"We Next"

"Comrade, have some tea." The owner of the stewed restaurant brought up a pot of tea, refilled the big tea cup in front of Yang Rui, interrupted him, and whispered: "Comrade, it's okay, drink less wine. , Don’t quarrel, if you continue to do this, the people from the neighborhood committee will have to say it."

He pouted backwards.

Yang Rui looked back and saw the aunt of the neighborhood committee with the red armband, standing in front of a tofu stall not far from here, staring at this side eagerly.

Yang Rui was certain that if it weren't for all foreigners sitting at this table, the aunt of the neighborhood committee would have rushed over.

"It's okay, we just chat." Yang Rui chuckled twice.

The owner of the stewed store said "Oh", and then said "You guys should be quiet", and he took the tea kettle and went to the tofu stall to report.

Yang Rui watched him walk away, shook his head, took a sip of tea, reorganized his mind, and continued: "How about similar classifications for Phase II? The milestone for one pass is US$20 million, and three passes are the mid-line. Through one more, an increase of 100 million US dollars"

Raymond cunningly said: "The budget for the second clinical phase is usually 600 million to 100 million US dollars. In this way, if two active substances pass the second clinical phase, we will pay you half of the budget."

"If two active substances pass the second phase of the clinical trial, it is also because the deferiprone active substance I synthesized is excellent, not your clinical trial." Yang Rui said simply: "The milestone is used to reward and compensate us. Work is not punishment."

"Calculated according to the maximum amount, seven compounds passed the first clinical phase. If BB is used, we have to pay 520,000 yuan."

"If you think there will be seven compounds that will pass the first clinical phase~www.NovelMTL.com~ you should choose a type a agreement, which only costs 20 million US dollars." Yang Rui raised his voice slightly.

Several people laughed happily.

This is the case with the gambling agreement. If you make a wrong bet, you will spend more money.

Raymond shrugged and said, "I just want to talk about possible costs."

"Even I dare not think about this possibility." Yang Rui laughed. He determined that the seven compounds here have a high probability of passing clinical phase I, but at most they can only pass four in clinical phase II. If you are unlucky, there will only be two or even one.

Clinical Phase I and Clinical Phase II are fundamentally different concepts.

"Comrade, were you talking about money just now?" The aunt of the neighborhood committee walked behind Yang Rui for some unknown time.

Yang Rui turned around in surprise and asked, "Is it talked about money, do you understand?"

The aunt smiled proudly and said, "English is nothing great. In our alley, there are many people who understand English."

At the entrance of the alley behind her, there were a few red scarves dangling under the street lamp.

Yang Rui praised: "Awesome."

"It's you who are great, doing business with foreigners, what are you selling?" Aunty smiled.

Yang Rui was unwilling to answer, and said, "It's nothing."

"There must be something, or else it will excite others. Comrade, which unit are you from." The aunt's eyes sharpened.

. . . . . .